Global Granulomatosis with Polyangiitis Drug Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Granulomatosis with Polyangiitis Drug market size was valued at US$ million in 2023. With growing demand in downstream market, the Granulomatosis with Polyangiitis Drug is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Granulomatosis with Polyangiitis Drug market. Granulomatosis with Polyangiitis Drug are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Granulomatosis with Polyangiitis Drug. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Granulomatosis with Polyangiitis Drug market.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Granulomatosis with Polyangiitis Drug market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Granulomatosis with Polyangiitis Drug market. It may include historical data, market segmentation by Type (e.g., Benralizumab, Avacopan), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Granulomatosis with Polyangiitis Drug market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Granulomatosis with Polyangiitis Drug market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Granulomatosis with Polyangiitis Drug industry. This include advancements in Granulomatosis with Polyangiitis Drug technology, Granulomatosis with Polyangiitis Drug new entrants, Granulomatosis with Polyangiitis Drug new investment, and other innovations that are shaping the future of Granulomatosis with Polyangiitis Drug.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Granulomatosis with Polyangiitis Drug market. It includes factors influencing customer ' purchasing decisions, preferences for Granulomatosis with Polyangiitis Drug product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Granulomatosis with Polyangiitis Drug market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Granulomatosis with Polyangiitis Drug market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Granulomatosis with Polyangiitis Drug market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Granulomatosis with Polyangiitis Drug industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Granulomatosis with Polyangiitis Drug market.
Market Segmentation:
Granulomatosis with Polyangiitis Drug market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
What is the 10-year outlook for the global Granulomatosis with Polyangiitis Drug market?
What factors are driving Granulomatosis with Polyangiitis Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Granulomatosis with Polyangiitis Drug market opportunities vary by end market size?
How does Granulomatosis with Polyangiitis Drug break out type, application?
According to our LPI (LP Information) latest study, the global Granulomatosis with Polyangiitis Drug market size was valued at US$ million in 2023. With growing demand in downstream market, the Granulomatosis with Polyangiitis Drug is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Granulomatosis with Polyangiitis Drug market. Granulomatosis with Polyangiitis Drug are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Granulomatosis with Polyangiitis Drug. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Granulomatosis with Polyangiitis Drug market.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Granulomatosis with Polyangiitis Drug market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Granulomatosis with Polyangiitis Drug market. It may include historical data, market segmentation by Type (e.g., Benralizumab, Avacopan), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Granulomatosis with Polyangiitis Drug market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Granulomatosis with Polyangiitis Drug market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Granulomatosis with Polyangiitis Drug industry. This include advancements in Granulomatosis with Polyangiitis Drug technology, Granulomatosis with Polyangiitis Drug new entrants, Granulomatosis with Polyangiitis Drug new investment, and other innovations that are shaping the future of Granulomatosis with Polyangiitis Drug.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Granulomatosis with Polyangiitis Drug market. It includes factors influencing customer ' purchasing decisions, preferences for Granulomatosis with Polyangiitis Drug product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Granulomatosis with Polyangiitis Drug market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Granulomatosis with Polyangiitis Drug market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Granulomatosis with Polyangiitis Drug market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Granulomatosis with Polyangiitis Drug industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Granulomatosis with Polyangiitis Drug market.
Market Segmentation:
Granulomatosis with Polyangiitis Drug market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- Benralizumab
- Avacopan
- Rituximab Biosimilar
- Others
- Hospital
- Clinic
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Bionovis SA
- Bristol-Myers Squibb Company
- ChemoCentryx Inc
- Coherus BioSciences Inc
- Genor BioPharma Co Ltd
- GlaxoSmithKline Plc
- Iltoo Pharma
- Panacea Biotec Ltd
- Sandoz International GmbH
- The International Biotechnology Center (IBC) Generium
What is the 10-year outlook for the global Granulomatosis with Polyangiitis Drug market?
What factors are driving Granulomatosis with Polyangiitis Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Granulomatosis with Polyangiitis Drug market opportunities vary by end market size?
How does Granulomatosis with Polyangiitis Drug break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Granulomatosis with Polyangiitis Drug Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Granulomatosis with Polyangiitis Drug by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Granulomatosis with Polyangiitis Drug by Country/Region, 2019, 2023 & 2030
2.2 Granulomatosis with Polyangiitis Drug Segment by Type
2.2.1 Benralizumab
2.2.2 Avacopan
2.2.3 Rituximab Biosimilar
2.2.4 Others
2.3 Granulomatosis with Polyangiitis Drug Sales by Type
2.3.1 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2019-2024)
2.3.2 Global Granulomatosis with Polyangiitis Drug Revenue and Market Share by Type (2019-2024)
2.3.3 Global Granulomatosis with Polyangiitis Drug Sale Price by Type (2019-2024)
2.4 Granulomatosis with Polyangiitis Drug Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Granulomatosis with Polyangiitis Drug Sales by Application
2.5.1 Global Granulomatosis with Polyangiitis Drug Sale Market Share by Application (2019-2024)
2.5.2 Global Granulomatosis with Polyangiitis Drug Revenue and Market Share by Application (2019-2024)
2.5.3 Global Granulomatosis with Polyangiitis Drug Sale Price by Application (2019-2024)
3 GLOBAL GRANULOMATOSIS WITH POLYANGIITIS DRUG BY COMPANY
3.1 Global Granulomatosis with Polyangiitis Drug Breakdown Data by Company
3.1.1 Global Granulomatosis with Polyangiitis Drug Annual Sales by Company (2019-2024)
3.1.2 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Company (2019-2024)
3.2 Global Granulomatosis with Polyangiitis Drug Annual Revenue by Company (2019-2024)
3.2.1 Global Granulomatosis with Polyangiitis Drug Revenue by Company (2019-2024)
3.2.2 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Company (2019-2024)
3.3 Global Granulomatosis with Polyangiitis Drug Sale Price by Company
3.4 Key Manufacturers Granulomatosis with Polyangiitis Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Granulomatosis with Polyangiitis Drug Product Location Distribution
3.4.2 Players Granulomatosis with Polyangiitis Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR GRANULOMATOSIS WITH POLYANGIITIS DRUG BY GEOGRAPHIC REGION
4.1 World Historic Granulomatosis with Polyangiitis Drug Market Size by Geographic Region (2019-2024)
4.1.1 Global Granulomatosis with Polyangiitis Drug Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Granulomatosis with Polyangiitis Drug Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Granulomatosis with Polyangiitis Drug Market Size by Country/Region (2019-2024)
4.2.1 Global Granulomatosis with Polyangiitis Drug Annual Sales by Country/Region (2019-2024)
4.2.2 Global Granulomatosis with Polyangiitis Drug Annual Revenue by Country/Region (2019-2024)
4.3 Americas Granulomatosis with Polyangiitis Drug Sales Growth
4.4 APAC Granulomatosis with Polyangiitis Drug Sales Growth
4.5 Europe Granulomatosis with Polyangiitis Drug Sales Growth
4.6 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Growth
5 AMERICAS
5.1 Americas Granulomatosis with Polyangiitis Drug Sales by Country
5.1.1 Americas Granulomatosis with Polyangiitis Drug Sales by Country (2019-2024)
5.1.2 Americas Granulomatosis with Polyangiitis Drug Revenue by Country (2019-2024)
5.2 Americas Granulomatosis with Polyangiitis Drug Sales by Type
5.3 Americas Granulomatosis with Polyangiitis Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Granulomatosis with Polyangiitis Drug Sales by Region
6.1.1 APAC Granulomatosis with Polyangiitis Drug Sales by Region (2019-2024)
6.1.2 APAC Granulomatosis with Polyangiitis Drug Revenue by Region (2019-2024)
6.2 APAC Granulomatosis with Polyangiitis Drug Sales by Type
6.3 APAC Granulomatosis with Polyangiitis Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Granulomatosis with Polyangiitis Drug by Country
7.1.1 Europe Granulomatosis with Polyangiitis Drug Sales by Country (2019-2024)
7.1.2 Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2019-2024)
7.2 Europe Granulomatosis with Polyangiitis Drug Sales by Type
7.3 Europe Granulomatosis with Polyangiitis Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Granulomatosis with Polyangiitis Drug by Country
8.1.1 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Country (2019-2024)
8.1.2 Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue by Country (2019-2024)
8.2 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Type
8.3 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Granulomatosis with Polyangiitis Drug
10.3 Manufacturing Process Analysis of Granulomatosis with Polyangiitis Drug
10.4 Industry Chain Structure of Granulomatosis with Polyangiitis Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Granulomatosis with Polyangiitis Drug Distributors
11.3 Granulomatosis with Polyangiitis Drug Customer
12 WORLD FORECAST REVIEW FOR GRANULOMATOSIS WITH POLYANGIITIS DRUG BY GEOGRAPHIC REGION
12.1 Global Granulomatosis with Polyangiitis Drug Market Size Forecast by Region
12.1.1 Global Granulomatosis with Polyangiitis Drug Forecast by Region (2025-2030)
12.1.2 Global Granulomatosis with Polyangiitis Drug Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Granulomatosis with Polyangiitis Drug Forecast by Type
12.7 Global Granulomatosis with Polyangiitis Drug Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Bionovis SA
13.1.1 Bionovis SA Company Information
13.1.2 Bionovis SA Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.1.3 Bionovis SA Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Bionovis SA Main Business Overview
13.1.5 Bionovis SA Latest Developments
13.2 Bristol-Myers Squibb Company
13.2.1 Bristol-Myers Squibb Company Company Information
13.2.2 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.2.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Bristol-Myers Squibb Company Main Business Overview
13.2.5 Bristol-Myers Squibb Company Latest Developments
13.3 ChemoCentryx Inc
13.3.1 ChemoCentryx Inc Company Information
13.3.2 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.3.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 ChemoCentryx Inc Main Business Overview
13.3.5 ChemoCentryx Inc Latest Developments
13.4 Coherus BioSciences Inc
13.4.1 Coherus BioSciences Inc Company Information
13.4.2 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.4.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Coherus BioSciences Inc Main Business Overview
13.4.5 Coherus BioSciences Inc Latest Developments
13.5 Genor BioPharma Co Ltd
13.5.1 Genor BioPharma Co Ltd Company Information
13.5.2 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.5.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Genor BioPharma Co Ltd Main Business Overview
13.5.5 Genor BioPharma Co Ltd Latest Developments
13.6 GlaxoSmithKline Plc
13.6.1 GlaxoSmithKline Plc Company Information
13.6.2 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.6.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 GlaxoSmithKline Plc Main Business Overview
13.6.5 GlaxoSmithKline Plc Latest Developments
13.7 Iltoo Pharma
13.7.1 Iltoo Pharma Company Information
13.7.2 Iltoo Pharma Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.7.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Iltoo Pharma Main Business Overview
13.7.5 Iltoo Pharma Latest Developments
13.8 Panacea Biotec Ltd
13.8.1 Panacea Biotec Ltd Company Information
13.8.2 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.8.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Panacea Biotec Ltd Main Business Overview
13.8.5 Panacea Biotec Ltd Latest Developments
13.9 Sandoz International GmbH
13.9.1 Sandoz International GmbH Company Information
13.9.2 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.9.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Sandoz International GmbH Main Business Overview
13.9.5 Sandoz International GmbH Latest Developments
13.10 The International Biotechnology Center (IBC) Generium
13.10.1 The International Biotechnology Center (IBC) Generium Company Information
13.10.2 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.10.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 The International Biotechnology Center (IBC) Generium Main Business Overview
13.10.5 The International Biotechnology Center (IBC) Generium Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Granulomatosis with Polyangiitis Drug Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Granulomatosis with Polyangiitis Drug by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Granulomatosis with Polyangiitis Drug by Country/Region, 2019, 2023 & 2030
2.2 Granulomatosis with Polyangiitis Drug Segment by Type
2.2.1 Benralizumab
2.2.2 Avacopan
2.2.3 Rituximab Biosimilar
2.2.4 Others
2.3 Granulomatosis with Polyangiitis Drug Sales by Type
2.3.1 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2019-2024)
2.3.2 Global Granulomatosis with Polyangiitis Drug Revenue and Market Share by Type (2019-2024)
2.3.3 Global Granulomatosis with Polyangiitis Drug Sale Price by Type (2019-2024)
2.4 Granulomatosis with Polyangiitis Drug Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Granulomatosis with Polyangiitis Drug Sales by Application
2.5.1 Global Granulomatosis with Polyangiitis Drug Sale Market Share by Application (2019-2024)
2.5.2 Global Granulomatosis with Polyangiitis Drug Revenue and Market Share by Application (2019-2024)
2.5.3 Global Granulomatosis with Polyangiitis Drug Sale Price by Application (2019-2024)
3 GLOBAL GRANULOMATOSIS WITH POLYANGIITIS DRUG BY COMPANY
3.1 Global Granulomatosis with Polyangiitis Drug Breakdown Data by Company
3.1.1 Global Granulomatosis with Polyangiitis Drug Annual Sales by Company (2019-2024)
3.1.2 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Company (2019-2024)
3.2 Global Granulomatosis with Polyangiitis Drug Annual Revenue by Company (2019-2024)
3.2.1 Global Granulomatosis with Polyangiitis Drug Revenue by Company (2019-2024)
3.2.2 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Company (2019-2024)
3.3 Global Granulomatosis with Polyangiitis Drug Sale Price by Company
3.4 Key Manufacturers Granulomatosis with Polyangiitis Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Granulomatosis with Polyangiitis Drug Product Location Distribution
3.4.2 Players Granulomatosis with Polyangiitis Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR GRANULOMATOSIS WITH POLYANGIITIS DRUG BY GEOGRAPHIC REGION
4.1 World Historic Granulomatosis with Polyangiitis Drug Market Size by Geographic Region (2019-2024)
4.1.1 Global Granulomatosis with Polyangiitis Drug Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Granulomatosis with Polyangiitis Drug Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Granulomatosis with Polyangiitis Drug Market Size by Country/Region (2019-2024)
4.2.1 Global Granulomatosis with Polyangiitis Drug Annual Sales by Country/Region (2019-2024)
4.2.2 Global Granulomatosis with Polyangiitis Drug Annual Revenue by Country/Region (2019-2024)
4.3 Americas Granulomatosis with Polyangiitis Drug Sales Growth
4.4 APAC Granulomatosis with Polyangiitis Drug Sales Growth
4.5 Europe Granulomatosis with Polyangiitis Drug Sales Growth
4.6 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Growth
5 AMERICAS
5.1 Americas Granulomatosis with Polyangiitis Drug Sales by Country
5.1.1 Americas Granulomatosis with Polyangiitis Drug Sales by Country (2019-2024)
5.1.2 Americas Granulomatosis with Polyangiitis Drug Revenue by Country (2019-2024)
5.2 Americas Granulomatosis with Polyangiitis Drug Sales by Type
5.3 Americas Granulomatosis with Polyangiitis Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Granulomatosis with Polyangiitis Drug Sales by Region
6.1.1 APAC Granulomatosis with Polyangiitis Drug Sales by Region (2019-2024)
6.1.2 APAC Granulomatosis with Polyangiitis Drug Revenue by Region (2019-2024)
6.2 APAC Granulomatosis with Polyangiitis Drug Sales by Type
6.3 APAC Granulomatosis with Polyangiitis Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Granulomatosis with Polyangiitis Drug by Country
7.1.1 Europe Granulomatosis with Polyangiitis Drug Sales by Country (2019-2024)
7.1.2 Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2019-2024)
7.2 Europe Granulomatosis with Polyangiitis Drug Sales by Type
7.3 Europe Granulomatosis with Polyangiitis Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Granulomatosis with Polyangiitis Drug by Country
8.1.1 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Country (2019-2024)
8.1.2 Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue by Country (2019-2024)
8.2 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Type
8.3 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Granulomatosis with Polyangiitis Drug
10.3 Manufacturing Process Analysis of Granulomatosis with Polyangiitis Drug
10.4 Industry Chain Structure of Granulomatosis with Polyangiitis Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Granulomatosis with Polyangiitis Drug Distributors
11.3 Granulomatosis with Polyangiitis Drug Customer
12 WORLD FORECAST REVIEW FOR GRANULOMATOSIS WITH POLYANGIITIS DRUG BY GEOGRAPHIC REGION
12.1 Global Granulomatosis with Polyangiitis Drug Market Size Forecast by Region
12.1.1 Global Granulomatosis with Polyangiitis Drug Forecast by Region (2025-2030)
12.1.2 Global Granulomatosis with Polyangiitis Drug Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Granulomatosis with Polyangiitis Drug Forecast by Type
12.7 Global Granulomatosis with Polyangiitis Drug Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Bionovis SA
13.1.1 Bionovis SA Company Information
13.1.2 Bionovis SA Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.1.3 Bionovis SA Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Bionovis SA Main Business Overview
13.1.5 Bionovis SA Latest Developments
13.2 Bristol-Myers Squibb Company
13.2.1 Bristol-Myers Squibb Company Company Information
13.2.2 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.2.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Bristol-Myers Squibb Company Main Business Overview
13.2.5 Bristol-Myers Squibb Company Latest Developments
13.3 ChemoCentryx Inc
13.3.1 ChemoCentryx Inc Company Information
13.3.2 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.3.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 ChemoCentryx Inc Main Business Overview
13.3.5 ChemoCentryx Inc Latest Developments
13.4 Coherus BioSciences Inc
13.4.1 Coherus BioSciences Inc Company Information
13.4.2 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.4.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Coherus BioSciences Inc Main Business Overview
13.4.5 Coherus BioSciences Inc Latest Developments
13.5 Genor BioPharma Co Ltd
13.5.1 Genor BioPharma Co Ltd Company Information
13.5.2 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.5.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Genor BioPharma Co Ltd Main Business Overview
13.5.5 Genor BioPharma Co Ltd Latest Developments
13.6 GlaxoSmithKline Plc
13.6.1 GlaxoSmithKline Plc Company Information
13.6.2 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.6.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 GlaxoSmithKline Plc Main Business Overview
13.6.5 GlaxoSmithKline Plc Latest Developments
13.7 Iltoo Pharma
13.7.1 Iltoo Pharma Company Information
13.7.2 Iltoo Pharma Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.7.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Iltoo Pharma Main Business Overview
13.7.5 Iltoo Pharma Latest Developments
13.8 Panacea Biotec Ltd
13.8.1 Panacea Biotec Ltd Company Information
13.8.2 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.8.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Panacea Biotec Ltd Main Business Overview
13.8.5 Panacea Biotec Ltd Latest Developments
13.9 Sandoz International GmbH
13.9.1 Sandoz International GmbH Company Information
13.9.2 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.9.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Sandoz International GmbH Main Business Overview
13.9.5 Sandoz International GmbH Latest Developments
13.10 The International Biotechnology Center (IBC) Generium
13.10.1 The International Biotechnology Center (IBC) Generium Company Information
13.10.2 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.10.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 The International Biotechnology Center (IBC) Generium Main Business Overview
13.10.5 The International Biotechnology Center (IBC) Generium Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Granulomatosis with Polyangiitis Drug Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Granulomatosis with Polyangiitis Drug Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Benralizumab
Table 4. Major Players of Avacopan
Table 5. Major Players of Rituximab Biosimilar
Table 6. Major Players of Others
Table 7. Global Granulomatosis with Polyangiitis Drug Sales by Type (2019-2024) & (K Pcs)
Table 8. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2019-2024)
Table 9. Global Granulomatosis with Polyangiitis Drug Revenue by Type (2019-2024) & ($ million)
Table 10. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2019-2024)
Table 11. Global Granulomatosis with Polyangiitis Drug Sale Price by Type (2019-2024) & (USD/Pcs)
Table 12. Global Granulomatosis with Polyangiitis Drug Sales by Application (2019-2024) & (K Pcs)
Table 13. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2019-2024)
Table 14. Global Granulomatosis with Polyangiitis Drug Revenue by Application (2019-2024)
Table 15. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2019-2024)
Table 16. Global Granulomatosis with Polyangiitis Drug Sale Price by Application (2019-2024) & (USD/Pcs)
Table 17. Global Granulomatosis with Polyangiitis Drug Sales by Company (2019-2024) & (K Pcs)
Table 18. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Company (2019-2024)
Table 19. Global Granulomatosis with Polyangiitis Drug Revenue by Company (2019-2024) ($ Millions)
Table 20. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Company (2019-2024)
Table 21. Global Granulomatosis with Polyangiitis Drug Sale Price by Company (2019-2024) & (USD/Pcs)
Table 22. Key Manufacturers Granulomatosis with Polyangiitis Drug Producing Area Distribution and Sales Area
Table 23. Players Granulomatosis with Polyangiitis Drug Products Offered
Table 24. Granulomatosis with Polyangiitis Drug Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Granulomatosis with Polyangiitis Drug Sales by Geographic Region (2019-2024) & (K Pcs)
Table 28. Global Granulomatosis with Polyangiitis Drug Sales Market Share Geographic Region (2019-2024)
Table 29. Global Granulomatosis with Polyangiitis Drug Revenue by Geographic Region (2019-2024) & ($ millions)
Table 30. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Geographic Region (2019-2024)
Table 31. Global Granulomatosis with Polyangiitis Drug Sales by Country/Region (2019-2024) & (K Pcs)
Table 32. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Country/Region (2019-2024)
Table 33. Global Granulomatosis with Polyangiitis Drug Revenue by Country/Region (2019-2024) & ($ millions)
Table 34. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Country/Region (2019-2024)
Table 35. Americas Granulomatosis with Polyangiitis Drug Sales by Country (2019-2024) & (K Pcs)
Table 36. Americas Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2019-2024)
Table 37. Americas Granulomatosis with Polyangiitis Drug Revenue by Country (2019-2024) & ($ Millions)
Table 38. Americas Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2019-2024)
Table 39. Americas Granulomatosis with Polyangiitis Drug Sales by Type (2019-2024) & (K Pcs)
Table 40. Americas Granulomatosis with Polyangiitis Drug Sales by Application (2019-2024) & (K Pcs)
Table 41. APAC Granulomatosis with Polyangiitis Drug Sales by Region (2019-2024) & (K Pcs)
Table 42. APAC Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2019-2024)
Table 43. APAC Granulomatosis with Polyangiitis Drug Revenue by Region (2019-2024) & ($ Millions)
Table 44. APAC Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2019-2024)
Table 45. APAC Granulomatosis with Polyangiitis Drug Sales by Type (2019-2024) & (K Pcs)
Table 46. APAC Granulomatosis with Polyangiitis Drug Sales by Application (2019-2024) & (K Pcs)
Table 47. Europe Granulomatosis with Polyangiitis Drug Sales by Country (2019-2024) & (K Pcs)
Table 48. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2019-2024)
Table 49. Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2019-2024) & ($ Millions)
Table 50. Europe Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2019-2024)
Table 51. Europe Granulomatosis with Polyangiitis Drug Sales by Type (2019-2024) & (K Pcs)
Table 52. Europe Granulomatosis with Polyangiitis Drug Sales by Application (2019-2024) & (K Pcs)
Table 53. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Country (2019-2024) & (K Pcs)
Table 54. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2019-2024)
Table 55. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue by Country (2019-2024) & ($ Millions)
Table 56. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2019-2024)
Table 57. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Type (2019-2024) & (K Pcs)
Table 58. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Application (2019-2024) & (K Pcs)
Table 59. Key Market Drivers & Growth Opportunities of Granulomatosis with Polyangiitis Drug
Table 60. Key Market Challenges & Risks of Granulomatosis with Polyangiitis Drug
Table 61. Key Industry Trends of Granulomatosis with Polyangiitis Drug
Table 62. Granulomatosis with Polyangiitis Drug Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Granulomatosis with Polyangiitis Drug Distributors List
Table 65. Granulomatosis with Polyangiitis Drug Customer List
Table 66. Global Granulomatosis with Polyangiitis Drug Sales Forecast by Region (2025-2030) & (K Pcs)
Table 67. Global Granulomatosis with Polyangiitis Drug Revenue Forecast by Region (2025-2030) & ($ millions)
Table 68. Americas Granulomatosis with Polyangiitis Drug Sales Forecast by Country (2025-2030) & (K Pcs)
Table 69. Americas Granulomatosis with Polyangiitis Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 70. APAC Granulomatosis with Polyangiitis Drug Sales Forecast by Region (2025-2030) & (K Pcs)
Table 71. APAC Granulomatosis with Polyangiitis Drug Revenue Forecast by Region (2025-2030) & ($ millions)
Table 72. Europe Granulomatosis with Polyangiitis Drug Sales Forecast by Country (2025-2030) & (K Pcs)
Table 73. Europe Granulomatosis with Polyangiitis Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Forecast by Country (2025-2030) & (K Pcs)
Table 75. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 76. Global Granulomatosis with Polyangiitis Drug Sales Forecast by Type (2025-2030) & (K Pcs)
Table 77. Global Granulomatosis with Polyangiitis Drug Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 78. Global Granulomatosis with Polyangiitis Drug Sales Forecast by Application (2025-2030) & (K Pcs)
Table 79. Global Granulomatosis with Polyangiitis Drug Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 80. Bionovis SA Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 81. Bionovis SA Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 82. Bionovis SA Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 83. Bionovis SA Main Business
Table 84. Bionovis SA Latest Developments
Table 85. Bristol-Myers Squibb Company Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 86. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 87. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 88. Bristol-Myers Squibb Company Main Business
Table 89. Bristol-Myers Squibb Company Latest Developments
Table 90. ChemoCentryx Inc Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 91. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 92. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 93. ChemoCentryx Inc Main Business
Table 94. ChemoCentryx Inc Latest Developments
Table 95. Coherus BioSciences Inc Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 96. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 97. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 98. Coherus BioSciences Inc Main Business
Table 99. Coherus BioSciences Inc Latest Developments
Table 100. Genor BioPharma Co Ltd Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 101. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 102. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 103. Genor BioPharma Co Ltd Main Business
Table 104. Genor BioPharma Co Ltd Latest Developments
Table 105. GlaxoSmithKline Plc Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 106. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 107. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 108. GlaxoSmithKline Plc Main Business
Table 109. GlaxoSmithKline Plc Latest Developments
Table 110. Iltoo Pharma Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 111. Iltoo Pharma Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 112. Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 113. Iltoo Pharma Main Business
Table 114. Iltoo Pharma Latest Developments
Table 115. Panacea Biotec Ltd Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 116. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 117. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 118. Panacea Biotec Ltd Main Business
Table 119. Panacea Biotec Ltd Latest Developments
Table 120. Sandoz International GmbH Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 121. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 122. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 123. Sandoz International GmbH Main Business
Table 124. Sandoz International GmbH Latest Developments
Table 125. The International Biotechnology Center (IBC) Generium Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 126. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 127. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 128. The International Biotechnology Center (IBC) Generium Main Business
Table 129. The International Biotechnology Center (IBC) Generium Latest Developments
Table 1. Granulomatosis with Polyangiitis Drug Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Granulomatosis with Polyangiitis Drug Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Benralizumab
Table 4. Major Players of Avacopan
Table 5. Major Players of Rituximab Biosimilar
Table 6. Major Players of Others
Table 7. Global Granulomatosis with Polyangiitis Drug Sales by Type (2019-2024) & (K Pcs)
Table 8. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2019-2024)
Table 9. Global Granulomatosis with Polyangiitis Drug Revenue by Type (2019-2024) & ($ million)
Table 10. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2019-2024)
Table 11. Global Granulomatosis with Polyangiitis Drug Sale Price by Type (2019-2024) & (USD/Pcs)
Table 12. Global Granulomatosis with Polyangiitis Drug Sales by Application (2019-2024) & (K Pcs)
Table 13. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2019-2024)
Table 14. Global Granulomatosis with Polyangiitis Drug Revenue by Application (2019-2024)
Table 15. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2019-2024)
Table 16. Global Granulomatosis with Polyangiitis Drug Sale Price by Application (2019-2024) & (USD/Pcs)
Table 17. Global Granulomatosis with Polyangiitis Drug Sales by Company (2019-2024) & (K Pcs)
Table 18. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Company (2019-2024)
Table 19. Global Granulomatosis with Polyangiitis Drug Revenue by Company (2019-2024) ($ Millions)
Table 20. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Company (2019-2024)
Table 21. Global Granulomatosis with Polyangiitis Drug Sale Price by Company (2019-2024) & (USD/Pcs)
Table 22. Key Manufacturers Granulomatosis with Polyangiitis Drug Producing Area Distribution and Sales Area
Table 23. Players Granulomatosis with Polyangiitis Drug Products Offered
Table 24. Granulomatosis with Polyangiitis Drug Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Granulomatosis with Polyangiitis Drug Sales by Geographic Region (2019-2024) & (K Pcs)
Table 28. Global Granulomatosis with Polyangiitis Drug Sales Market Share Geographic Region (2019-2024)
Table 29. Global Granulomatosis with Polyangiitis Drug Revenue by Geographic Region (2019-2024) & ($ millions)
Table 30. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Geographic Region (2019-2024)
Table 31. Global Granulomatosis with Polyangiitis Drug Sales by Country/Region (2019-2024) & (K Pcs)
Table 32. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Country/Region (2019-2024)
Table 33. Global Granulomatosis with Polyangiitis Drug Revenue by Country/Region (2019-2024) & ($ millions)
Table 34. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Country/Region (2019-2024)
Table 35. Americas Granulomatosis with Polyangiitis Drug Sales by Country (2019-2024) & (K Pcs)
Table 36. Americas Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2019-2024)
Table 37. Americas Granulomatosis with Polyangiitis Drug Revenue by Country (2019-2024) & ($ Millions)
Table 38. Americas Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2019-2024)
Table 39. Americas Granulomatosis with Polyangiitis Drug Sales by Type (2019-2024) & (K Pcs)
Table 40. Americas Granulomatosis with Polyangiitis Drug Sales by Application (2019-2024) & (K Pcs)
Table 41. APAC Granulomatosis with Polyangiitis Drug Sales by Region (2019-2024) & (K Pcs)
Table 42. APAC Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2019-2024)
Table 43. APAC Granulomatosis with Polyangiitis Drug Revenue by Region (2019-2024) & ($ Millions)
Table 44. APAC Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2019-2024)
Table 45. APAC Granulomatosis with Polyangiitis Drug Sales by Type (2019-2024) & (K Pcs)
Table 46. APAC Granulomatosis with Polyangiitis Drug Sales by Application (2019-2024) & (K Pcs)
Table 47. Europe Granulomatosis with Polyangiitis Drug Sales by Country (2019-2024) & (K Pcs)
Table 48. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2019-2024)
Table 49. Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2019-2024) & ($ Millions)
Table 50. Europe Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2019-2024)
Table 51. Europe Granulomatosis with Polyangiitis Drug Sales by Type (2019-2024) & (K Pcs)
Table 52. Europe Granulomatosis with Polyangiitis Drug Sales by Application (2019-2024) & (K Pcs)
Table 53. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Country (2019-2024) & (K Pcs)
Table 54. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2019-2024)
Table 55. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue by Country (2019-2024) & ($ Millions)
Table 56. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2019-2024)
Table 57. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Type (2019-2024) & (K Pcs)
Table 58. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Application (2019-2024) & (K Pcs)
Table 59. Key Market Drivers & Growth Opportunities of Granulomatosis with Polyangiitis Drug
Table 60. Key Market Challenges & Risks of Granulomatosis with Polyangiitis Drug
Table 61. Key Industry Trends of Granulomatosis with Polyangiitis Drug
Table 62. Granulomatosis with Polyangiitis Drug Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Granulomatosis with Polyangiitis Drug Distributors List
Table 65. Granulomatosis with Polyangiitis Drug Customer List
Table 66. Global Granulomatosis with Polyangiitis Drug Sales Forecast by Region (2025-2030) & (K Pcs)
Table 67. Global Granulomatosis with Polyangiitis Drug Revenue Forecast by Region (2025-2030) & ($ millions)
Table 68. Americas Granulomatosis with Polyangiitis Drug Sales Forecast by Country (2025-2030) & (K Pcs)
Table 69. Americas Granulomatosis with Polyangiitis Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 70. APAC Granulomatosis with Polyangiitis Drug Sales Forecast by Region (2025-2030) & (K Pcs)
Table 71. APAC Granulomatosis with Polyangiitis Drug Revenue Forecast by Region (2025-2030) & ($ millions)
Table 72. Europe Granulomatosis with Polyangiitis Drug Sales Forecast by Country (2025-2030) & (K Pcs)
Table 73. Europe Granulomatosis with Polyangiitis Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Forecast by Country (2025-2030) & (K Pcs)
Table 75. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 76. Global Granulomatosis with Polyangiitis Drug Sales Forecast by Type (2025-2030) & (K Pcs)
Table 77. Global Granulomatosis with Polyangiitis Drug Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 78. Global Granulomatosis with Polyangiitis Drug Sales Forecast by Application (2025-2030) & (K Pcs)
Table 79. Global Granulomatosis with Polyangiitis Drug Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 80. Bionovis SA Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 81. Bionovis SA Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 82. Bionovis SA Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 83. Bionovis SA Main Business
Table 84. Bionovis SA Latest Developments
Table 85. Bristol-Myers Squibb Company Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 86. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 87. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 88. Bristol-Myers Squibb Company Main Business
Table 89. Bristol-Myers Squibb Company Latest Developments
Table 90. ChemoCentryx Inc Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 91. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 92. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 93. ChemoCentryx Inc Main Business
Table 94. ChemoCentryx Inc Latest Developments
Table 95. Coherus BioSciences Inc Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 96. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 97. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 98. Coherus BioSciences Inc Main Business
Table 99. Coherus BioSciences Inc Latest Developments
Table 100. Genor BioPharma Co Ltd Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 101. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 102. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 103. Genor BioPharma Co Ltd Main Business
Table 104. Genor BioPharma Co Ltd Latest Developments
Table 105. GlaxoSmithKline Plc Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 106. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 107. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 108. GlaxoSmithKline Plc Main Business
Table 109. GlaxoSmithKline Plc Latest Developments
Table 110. Iltoo Pharma Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 111. Iltoo Pharma Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 112. Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 113. Iltoo Pharma Main Business
Table 114. Iltoo Pharma Latest Developments
Table 115. Panacea Biotec Ltd Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 116. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 117. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 118. Panacea Biotec Ltd Main Business
Table 119. Panacea Biotec Ltd Latest Developments
Table 120. Sandoz International GmbH Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 121. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 122. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 123. Sandoz International GmbH Main Business
Table 124. Sandoz International GmbH Latest Developments
Table 125. The International Biotechnology Center (IBC) Generium Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 126. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 127. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 128. The International Biotechnology Center (IBC) Generium Main Business
Table 129. The International Biotechnology Center (IBC) Generium Latest Developments
LIST OF FIGURES
Figure 1. Picture of Granulomatosis with Polyangiitis Drug
Figure 2. Granulomatosis with Polyangiitis Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Granulomatosis with Polyangiitis Drug Sales Growth Rate 2019-2030 (K Pcs)
Figure 7. Global Granulomatosis with Polyangiitis Drug Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Granulomatosis with Polyangiitis Drug Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Benralizumab
Figure 10. Product Picture of Avacopan
Figure 11. Product Picture of Rituximab Biosimilar
Figure 12. Product Picture of Others
Figure 13. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type in 2023
Figure 14. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2019-2024)
Figure 15. Granulomatosis with Polyangiitis Drug Consumed in Hospital
Figure 16. Global Granulomatosis with Polyangiitis Drug Market: Hospital (2019-2024) & (K Pcs)
Figure 17. Granulomatosis with Polyangiitis Drug Consumed in Clinic
Figure 18. Global Granulomatosis with Polyangiitis Drug Market: Clinic (2019-2024) & (K Pcs)
Figure 19. Granulomatosis with Polyangiitis Drug Consumed in Others
Figure 20. Global Granulomatosis with Polyangiitis Drug Market: Others (2019-2024) & (K Pcs)
Figure 21. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2023)
Figure 22. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application in 2023
Figure 23. Granulomatosis with Polyangiitis Drug Sales Market by Company in 2023 (K Pcs)
Figure 24. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Company in 2023
Figure 25. Granulomatosis with Polyangiitis Drug Revenue Market by Company in 2023 ($ Million)
Figure 26. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Company in 2023
Figure 27. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Geographic Region (2019-2024)
Figure 28. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Geographic Region in 2023
Figure 29. Americas Granulomatosis with Polyangiitis Drug Sales 2019-2024 (K Pcs)
Figure 30. Americas Granulomatosis with Polyangiitis Drug Revenue 2019-2024 ($ Millions)
Figure 31. APAC Granulomatosis with Polyangiitis Drug Sales 2019-2024 (K Pcs)
Figure 32. APAC Granulomatosis with Polyangiitis Drug Revenue 2019-2024 ($ Millions)
Figure 33. Europe Granulomatosis with Polyangiitis Drug Sales 2019-2024 (K Pcs)
Figure 34. Europe Granulomatosis with Polyangiitis Drug Revenue 2019-2024 ($ Millions)
Figure 35. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales 2019-2024 (K Pcs)
Figure 36. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue 2019-2024 ($ Millions)
Figure 37. Americas Granulomatosis with Polyangiitis Drug Sales Market Share by Country in 2023
Figure 38. Americas Granulomatosis with Polyangiitis Drug Revenue Market Share by Country in 2023
Figure 39. Americas Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2019-2024)
Figure 40. Americas Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2019-2024)
Figure 41. United States Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 42. Canada Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 43. Mexico Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 44. Brazil Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 45. APAC Granulomatosis with Polyangiitis Drug Sales Market Share by Region in 2023
Figure 46. APAC Granulomatosis with Polyangiitis Drug Revenue Market Share by Regions in 2023
Figure 47. APAC Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2019-2024)
Figure 48. APAC Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2019-2024)
Figure 49. China Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 50. Japan Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 51. South Korea Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 52. Southeast Asia Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 53. India Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 54. Australia Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 55. China Taiwan Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 56. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Country in 2023
Figure 57. Europe Granulomatosis with Polyangiitis Drug Revenue Market Share by Country in 2023
Figure 58. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2019-2024)
Figure 59. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2019-2024)
Figure 60. Germany Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 61. France Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 62. UK Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 63. Italy Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 64. Russia Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 65. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Country in 2023
Figure 66. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue Market Share by Country in 2023
Figure 67. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2019-2024)
Figure 68. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2019-2024)
Figure 69. Egypt Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 70. South Africa Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 71. Israel Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 72. Turkey Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 73. GCC Country Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Granulomatosis with Polyangiitis Drug in 2023
Figure 75. Manufacturing Process Analysis of Granulomatosis with Polyangiitis Drug
Figure 76. Industry Chain Structure of Granulomatosis with Polyangiitis Drug
Figure 77. Channels of Distribution
Figure 78. Global Granulomatosis with Polyangiitis Drug Sales Market Forecast by Region (2025-2030)
Figure 79. Global Granulomatosis with Polyangiitis Drug Revenue Market Share Forecast by Region (2025-2030)
Figure 80. Global Granulomatosis with Polyangiitis Drug Sales Market Share Forecast by Type (2025-2030)
Figure 81. Global Granulomatosis with Polyangiitis Drug Revenue Market Share Forecast by Type (2025-2030)
Figure 82. Global Granulomatosis with Polyangiitis Drug Sales Market Share Forecast by Application (2025-2030)
Figure 83. Global Granulomatosis with Polyangiitis Drug Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Granulomatosis with Polyangiitis Drug
Figure 2. Granulomatosis with Polyangiitis Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Granulomatosis with Polyangiitis Drug Sales Growth Rate 2019-2030 (K Pcs)
Figure 7. Global Granulomatosis with Polyangiitis Drug Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Granulomatosis with Polyangiitis Drug Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Benralizumab
Figure 10. Product Picture of Avacopan
Figure 11. Product Picture of Rituximab Biosimilar
Figure 12. Product Picture of Others
Figure 13. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type in 2023
Figure 14. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2019-2024)
Figure 15. Granulomatosis with Polyangiitis Drug Consumed in Hospital
Figure 16. Global Granulomatosis with Polyangiitis Drug Market: Hospital (2019-2024) & (K Pcs)
Figure 17. Granulomatosis with Polyangiitis Drug Consumed in Clinic
Figure 18. Global Granulomatosis with Polyangiitis Drug Market: Clinic (2019-2024) & (K Pcs)
Figure 19. Granulomatosis with Polyangiitis Drug Consumed in Others
Figure 20. Global Granulomatosis with Polyangiitis Drug Market: Others (2019-2024) & (K Pcs)
Figure 21. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2023)
Figure 22. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application in 2023
Figure 23. Granulomatosis with Polyangiitis Drug Sales Market by Company in 2023 (K Pcs)
Figure 24. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Company in 2023
Figure 25. Granulomatosis with Polyangiitis Drug Revenue Market by Company in 2023 ($ Million)
Figure 26. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Company in 2023
Figure 27. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Geographic Region (2019-2024)
Figure 28. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Geographic Region in 2023
Figure 29. Americas Granulomatosis with Polyangiitis Drug Sales 2019-2024 (K Pcs)
Figure 30. Americas Granulomatosis with Polyangiitis Drug Revenue 2019-2024 ($ Millions)
Figure 31. APAC Granulomatosis with Polyangiitis Drug Sales 2019-2024 (K Pcs)
Figure 32. APAC Granulomatosis with Polyangiitis Drug Revenue 2019-2024 ($ Millions)
Figure 33. Europe Granulomatosis with Polyangiitis Drug Sales 2019-2024 (K Pcs)
Figure 34. Europe Granulomatosis with Polyangiitis Drug Revenue 2019-2024 ($ Millions)
Figure 35. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales 2019-2024 (K Pcs)
Figure 36. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue 2019-2024 ($ Millions)
Figure 37. Americas Granulomatosis with Polyangiitis Drug Sales Market Share by Country in 2023
Figure 38. Americas Granulomatosis with Polyangiitis Drug Revenue Market Share by Country in 2023
Figure 39. Americas Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2019-2024)
Figure 40. Americas Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2019-2024)
Figure 41. United States Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 42. Canada Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 43. Mexico Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 44. Brazil Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 45. APAC Granulomatosis with Polyangiitis Drug Sales Market Share by Region in 2023
Figure 46. APAC Granulomatosis with Polyangiitis Drug Revenue Market Share by Regions in 2023
Figure 47. APAC Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2019-2024)
Figure 48. APAC Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2019-2024)
Figure 49. China Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 50. Japan Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 51. South Korea Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 52. Southeast Asia Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 53. India Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 54. Australia Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 55. China Taiwan Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 56. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Country in 2023
Figure 57. Europe Granulomatosis with Polyangiitis Drug Revenue Market Share by Country in 2023
Figure 58. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2019-2024)
Figure 59. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2019-2024)
Figure 60. Germany Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 61. France Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 62. UK Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 63. Italy Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 64. Russia Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 65. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Country in 2023
Figure 66. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue Market Share by Country in 2023
Figure 67. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2019-2024)
Figure 68. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2019-2024)
Figure 69. Egypt Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 70. South Africa Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 71. Israel Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 72. Turkey Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 73. GCC Country Granulomatosis with Polyangiitis Drug Revenue Growth 2019-2024 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Granulomatosis with Polyangiitis Drug in 2023
Figure 75. Manufacturing Process Analysis of Granulomatosis with Polyangiitis Drug
Figure 76. Industry Chain Structure of Granulomatosis with Polyangiitis Drug
Figure 77. Channels of Distribution
Figure 78. Global Granulomatosis with Polyangiitis Drug Sales Market Forecast by Region (2025-2030)
Figure 79. Global Granulomatosis with Polyangiitis Drug Revenue Market Share Forecast by Region (2025-2030)
Figure 80. Global Granulomatosis with Polyangiitis Drug Sales Market Share Forecast by Type (2025-2030)
Figure 81. Global Granulomatosis with Polyangiitis Drug Revenue Market Share Forecast by Type (2025-2030)
Figure 82. Global Granulomatosis with Polyangiitis Drug Sales Market Share Forecast by Application (2025-2030)
Figure 83. Global Granulomatosis with Polyangiitis Drug Revenue Market Share Forecast by Application (2025-2030)
